Abbott Labs Files Q1 2024 10-Q
Ticker: ABT · Form: 10-Q · Filed: 2024-05-02T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
Abbott Labs Q1 2024 10-Q is in. Check financials.
AI Summary
Abbott Laboratories filed its 10-Q for the period ending March 31, 2024. The company reported financial results for the first quarter of 2024, detailing its revenues, expenses, and net income. Key financial figures and balance sheet information were presented, reflecting the company's performance and financial position during the reporting period.
Why It Matters
This filing provides investors with a detailed look at Abbott Laboratories' financial health and operational performance for the first quarter of 2024, influencing investment decisions.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing standard financial information.
Key Numbers
- 20240331 — Period End Date (Quarterly reporting period)
- 20240502 — Filing Date (Date the report was submitted)
Key Players & Entities
- ABBOTT LABORATORIES (company) — Filer
- 0001628280-24-020011 (filing_id) — Accession Number
- 20240331 (date) — Period of Report
- 20240502 (date) — Filing Date
FAQ
What was Abbott Laboratories' total revenue for the first quarter of 2024?
The filing does not explicitly state the total revenue for Q1 2024 in the provided header information. A full review of the 10-Q document would be required to determine this figure.
What is the fiscal year end for Abbott Laboratories?
The fiscal year end for Abbott Laboratories is December 31.
What is the Standard Industrial Classification code for Abbott Laboratories?
The SIC code for Abbott Laboratories is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 2, 2024.
What is the SEC file number for Abbott Laboratories?
The SEC file number for Abbott Laboratories is 001-02189.
From the Filing
0001628280-24-020011.txt : 20240502 0001628280-24-020011.hdr.sgml : 20240502 20240502161110 ACCESSION NUMBER: 0001628280-24-020011 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 24908340 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 10-Q 1 abt-20240331.htm 10-Q abt-20240331 0000001800 12-31 2024 Q1 false P12M 0000001800 2024-01-01 2024-03-31 0000001800 exch:XNYS 2024-01-01 2024-03-31 0000001800 exch:XCHI 2024-01-01 2024-03-31 0000001800 2024-03-31 xbrli:shares iso4217:USD 0000001800 2023-01-01 2023-03-31 iso4217:USD xbrli:shares 0000001800 2023-12-31 0000001800 us-gaap:CommonStockMember 2023-12-31 0000001800 us-gaap:CommonStockMember 2022-12-31 0000001800 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000001800 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000001800 us-gaap:CommonStockMember 2024-03-31 0000001800 us-gaap:CommonStockMember 2023-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2023-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2022-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2024-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2023-03-31 0000001800 us-gaap:RetainedEarningsMember 2023-12-31 0000001800 us-gaap:RetainedEarningsMember 2022-12-31 0000001800 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000001800 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000001800 us-gaap:RetainedEarningsMember 2024-03-31 0000001800 us-gaap:RetainedEarningsMember 2023-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2023-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2022-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2024-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2023-03-31 0000001800 2022-12-31 0000001800 2023-03-31 abt:segment 0000001800 us-gaap:OperatingSegmentsMember abt:KeyEmergingMarketsMember abt:EstablishedPharmaceuticalProductsMember country:US 2024-01-01 2024-03-31 0000001800 us-gaap:NonUsMember us-gaap:OperatingSegmentsMember abt:KeyEmergingMarketsMember abt:EstablishedPharmaceuticalProductsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:KeyEmergingMarketsMember abt:EstablishedPharmaceuticalProductsMember 2024-01-01 2024-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:KeyEmergingMarketsMember abt:EstablishedPharmaceuticalProductsMember country:US 2023-01-01 2023-03-31 0000001800 us-gaap:NonUsMember us-gaap:OperatingSegmentsMember abt:KeyEmergingMarketsMember abt:EstablishedPharmaceuticalProductsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:KeyEmergingMarketsMember abt:EstablishedPharmaceuticalProductsMember 2023-01-01 2023-03-31 0000001800 us-gaap:OperatingSeg